Literature DB >> 31642038

Development of an anti-CD45RA-quantum dots conjugated scFv to detect leukemic cancer stem cells.

Shima Moradi-Kalbolandi1, Fariba Dashtestani1, Malihe Salehi1, Neda Jalili1, Keivan Majidzadeh-A1, Reza Rahighi2, Amir Yadegari3, Leila Farahmand4.   

Abstract

Leukemic cancer stem cells (LSCs), aberrantly overexpressing CD45RA are among the major causes of relapse following chemotherapy in patients with acute myeloid leukemia and serve as a highly sensitive marker for predicting relapse occurrence following chemotherapy. The main purpose of current study was to develop a sensitive approach for detecting LSCs based on a conjugate of an anti-CD45 scFv and quantum dot. The variable light and heavy chain sequences of a recently developed anti-CD45RA monoclonal antibody were derived from hybridoma cells and PCR amplified to construct scFv. Following insertion of scFv gene into a pET32a-lic vector and expression in Escherichia coli and purification, the purified scFv, was conjugated with carbon dots (C dots) and used for the detection of CD45RA +cells while CD45RA-cells served as negative control. Subsequently, Functional activity of the conjugate was analyzed by flow cytometry and ICC to detect the cell surface antigen binding and detection ability. Based on results, purified CD45RA scFv conjugated C dots could specifically recognize CD45RA positive cells, but not any CD45RA negative ones. In conclusion, here we developed a low-cost but very efficient approach for detection of CD45RA positive cells including LSCs.

Entities:  

Keywords:  AML; CD45RA; Carbon dots; Conjugation; Leukemic cancer stem cell; scFv

Mesh:

Substances:

Year:  2019        PMID: 31642038     DOI: 10.1007/s11033-019-05122-w

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  21 in total

Review 1.  Properties of end-stage human T cells defined by CD45RA re-expression.

Authors:  Sian M Henson; Natalie E Riddell; Arne N Akbar
Journal:  Curr Opin Immunol       Date:  2012-05-01       Impact factor: 7.486

2.  Carbon Dots as Nontoxic and High-Performance Fluorescence Imaging Agents.

Authors:  Sheng-Tao Yang; Xin Wang; Haifang Wang; Fushen Lu; Pengju G Luo; Li Cao; Mohammed J Meziani; Jia-Hui Liu; Yuanfang Liu; Min Chen; Yipu Huang; Ya-Ping Sun
Journal:  J Phys Chem C Nanomater Interfaces       Date:  2009-09-28       Impact factor: 4.126

3.  A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia.

Authors:  Jonathan M Gerber; B Douglas Smith; Brownhilda Ngwang; Hao Zhang; Milada S Vala; Laura Morsberger; Steven Galkin; Michael I Collector; Brandy Perkins; Mark J Levis; Constance A Griffin; Saul J Sharkis; Michael J Borowitz; Judith E Karp; Richard J Jones
Journal:  Blood       Date:  2012-01-19       Impact factor: 22.113

4.  Single-chain antigen-binding proteins.

Authors:  R E Bird; K D Hardman; J W Jacobson; S Johnson; B M Kaufman; S M Lee; T Lee; S H Pope; G S Riordan; M Whitlow
Journal:  Science       Date:  1988-10-21       Impact factor: 47.728

Review 5.  Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors.

Authors:  Robert A Beckman; Louis M Weiner; Hugh M Davis
Journal:  Cancer       Date:  2007-01-15       Impact factor: 6.860

6.  A genetically engineered anti-CD45 single-chain antibody-streptavidin fusion protein for pretargeted radioimmunotherapy of hematologic malignancies.

Authors:  Yukang Lin; John M Pagel; Donald Axworthy; Anastasia Pantelias; Nathan Hedin; Oliver W Press
Journal:  Cancer Res       Date:  2006-04-01       Impact factor: 12.701

7.  High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.

Authors:  Monique Terwijn; Wim L J van Putten; Angèle Kelder; Vincent H J van der Velden; Rik A Brooimans; Thomas Pabst; Johan Maertens; Nancy Boeckx; Georgine E de Greef; Peter J M Valk; Frank W M B Preijers; Peter C Huijgens; Angelika M Dräger; Urs Schanz; Mojca Jongen-Lavrecic; Bart J Biemond; Jakob R Passweg; Michel van Gelder; Pierre Wijermans; Carlos Graux; Mario Bargetzi; Marie-Cecile Legdeur; Jurgen Kuball; Okke de Weerdt; Yves Chalandon; Urs Hess; Leo F Verdonck; Jan W Gratama; Yvonne J M Oussoren; Willemijn J Scholten; Jennita Slomp; Alexander N Snel; Marie-Christiane Vekemans; Bob Löwenberg; Gert J Ossenkoppele; Gerrit J Schuurhuis
Journal:  J Clin Oncol       Date:  2013-09-23       Impact factor: 44.544

8.  Characterization of Monoclonal Antibodies against Human Leukocyte Common Antigen (CD45).

Authors:  Hyang-Mi Shin; Woon-Dong Cho; Geon-Kook Lee; Seon-Hwa Lee; Kyung-Mee Lee; Gil-Yong Ji; Sang-Soon Yoon; Ji-Hae Koo; Ho-Chang Lee; Ki-Hyeong Lee; Hyung-Geun Song
Journal:  Immune Netw       Date:  2011-04-30       Impact factor: 6.303

9.  A compact phage display human scFv library for selection of antibodies to a wide variety of antigens.

Authors:  Potjamas Pansri; Nanthnit Jaruseranee; Kuntalee Rangnoi; Peter Kristensen; Montarop Yamabhai
Journal:  BMC Biotechnol       Date:  2009-01-29       Impact factor: 2.563

10.  Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia.

Authors:  Monique Terwijn; Wendelien Zeijlemaker; Angèle Kelder; Arjo P Rutten; Alexander N Snel; Willemijn J Scholten; Thomas Pabst; Gregor Verhoef; Bob Löwenberg; Sonja Zweegman; Gert J Ossenkoppele; Gerrit J Schuurhuis
Journal:  PLoS One       Date:  2014-09-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.